These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 20668436)

  • 1. Is glycogen synthase kinase-3 a central modulator in mood regulation?
    Li X; Jope RS
    Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
    Cole AR
    FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.
    Jope RS
    Front Mol Neurosci; 2011; 4():16. PubMed ID: 21886606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
    Jope RS; Roh MS
    Curr Drug Targets; 2006 Nov; 7(11):1421-34. PubMed ID: 17100582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
    Manduca JD; Thériault RK; Perreault ML
    Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances.
    Polter A; Beurel E; Yang S; Garner R; Song L; Miller CA; Sweatt JD; McMahon L; Bartolucci AA; Li X; Jope RS
    Neuropsychopharmacology; 2010 Jul; 35(8):1761-74. PubMed ID: 20357757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.
    Caberlotto L; Carboni L; Zanderigo F; Andreetta F; Andreoli M; Gentile G; Razzoli M
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Oct; 386(10):893-903. PubMed ID: 23793101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3 levels and phosphorylation undergo large fluctuations in mouse brain during development.
    Beurel E; Mines MA; Song L; Jope RS
    Bipolar Disord; 2012 Dec; 14(8):822-30. PubMed ID: 23167932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.
    Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ
    ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
    Gould TD
    Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders.
    Beurel E
    Neuroimmunomodulation; 2014; 21(2-3):140-4. PubMed ID: 24557047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase.
    MacAulay K; Hajduch E; Blair AS; Coghlan MP; Smith SA; Hundal HS
    Eur J Biochem; 2003 Sep; 270(18):3829-38. PubMed ID: 12950267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3: more than a namesake.
    Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A
    Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors.
    Chen L; Zhou W; Chen PC; Gaisina I; Yang S; Li X
    Mol Pharmacol; 2011 Jun; 79(6):974-86. PubMed ID: 21372171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.